ASX Announcements, Company News 30 Apr 2026 Orthocell achieves first Remplir™ sales in US$75 million Canadian Market Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in… Orthocell
ASX Announcements, Company News 20 Apr 2026 Orthocell reports continued growth and strong US momentum in March 2026 quarter Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial… Orthocell
ASX Announcements, Company News 17 Apr 2026 First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs… Orthocell
Video 15 Apr 2026 Orthocell secures Remplir™ approval across U.S. Department of Defence Hospital Network Orthocell has secured approval for Remplir™ to be used across the United States Department of Defence and Veterans Affairs (VA)… Orthocell
Company News 10 Apr 2026 Remplir™ Exempt from US Pharma Tariffs Due to Medical Device Status Recent coverage has highlighted that Orthocell’s flagship nerve repair product, Remplir™, is expected to be exempt from newly proposed US… Orthocell
Company News, Video 01 Apr 2026 Investor Presentations | March 2026 Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on… Orthocell
